西维美林(Cevimeline Hydrochloride) - 药物靶点：M3 receptor_在研适应症：干燥综合征，抗合成酶综合征，口干症_专利_临床

概要

基本信息

药物类型

小分子化药

别名

2-Methyspiro(1,3-oxathiolane-5,3)quinuclidine、Cevimeline、Cevimeline Hydrochloride Hydrate

+ [17]

靶点

M3 receptor

作用机制

M3 receptor激动剂(毒蕈碱型乙酰胆碱受体M3激动剂)

治疗领域

免疫系统疾病神经系统疾病眼部疾病+ [2]

在研适应症

干燥综合征抗合成酶综合征口干症

非在研适应症

阿尔茨海默症痴呆头颈部肿瘤

原研机构

Snow Brand Milk Products Co., Ltd.

在研机构

Alfresa Pharma Corp.

Daiichi Sankyo Co., Ltd.

Cosette Pharmaceuticals, Inc.初创企业

+ [1]

非在研机构

Snow Brand Milk Products Co., Ltd.

最高研发阶段批准上市

首次获批日期

美国 (2000-01-11),

抗合成酶综合征口干症

最高研发阶段(中国)-

特殊审评-

登录后查看首次获批时间轴

结构

分子式C10H17NOS

InChIKeyWUTYZMFRCNBCHQ-CSEYRULYSA-N

CAS号107233-08-9

查看全部结构式(3)

关联

7

项与西维美林相关的临床试验

ChiCTR2000033420 / Recruiting早期临床1期IIT

Investigating the clinical efficacy of cevimeline in improving the symptoms of primary sjogren syndrome

开始日期2020-06-01

申办/合作机构-

NCT01903109 / Completed早期临床1期

A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fed Conditions

The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fed conditions

开始日期2009-02-28

申办/合作机构

Roxane Laboratories, Inc.

NCT01903122 / Completed早期临床1期

A Single Dose, Two-Period, Two-Treatment, Two-Way Crossover Bioequivalence Study of Cevimeline 30 mg Capsules Under Fasted Conditions

The objective of this study was to prove the bioequivalence of Roxane Laboratories' Cevimeline 30 mg under fasted conditions

开始日期2009-02-28

申办/合作机构

Roxane Laboratories, Inc.

100 项与西维美林相关的临床结果

登录后查看更多信息

100 项与西维美林相关的转化医学

登录后查看更多信息

100 项与西维美林相关的专利（医药）

登录后查看更多信息

204

项与西维美林相关的文献（医药）

2022-12-23·Science Advances

Long-term functional regeneration of radiation-damaged salivary glands through delivery of a neurogenic hydrogel

Article

作者: Sinada, Hanan ; Cruz Pacheco, Noel ; Gaylord, Eliza A. ; Alsberg, Eben ; Li, Jianlong ; Bahney, Chelsea S. ; Berthoin, Lionel ; Jeon, Oju ; Knox, Sarah M. ; May, Alison J. ; Chang, Jiun Chiun ; Mohabbat, Seayar ; Sudiwala, Sonia ; Lombaert, Isabelle M.A.

Salivary gland acinar cells are severely depleted after radiotherapy for head and neck cancer, leading to loss of saliva and extensive oro-digestive complications. With no regenerative therapies available, organ dysfunction is irreversible. Here, using the adult murine system, we demonstrate that radiation-damaged salivary glands can be functionally regenerated via sustained delivery of the neurogenic muscarinic receptor agonist cevimeline. We show that endogenous gland repair coincides with increased nerve activity and acinar cell division that is limited to the first week after radiation, with extensive acinar cell degeneration, dysfunction, and cholinergic denervation occurring thereafter. However, we found that mimicking cholinergic muscarinic input via sustained local delivery of a cevimeline–alginate hydrogel was sufficient to regenerate innervated acini and retain physiological saliva secretion at nonirradiated levels over the long term (>3 months). Thus, we reveal a previously unknown regenerative approach for restoring epithelial organ structure and function that has extensive implications for human patients.

2022-12-01·Journal of Medical Case Reports

Suspected cholinergic toxicity due to cevimeline hydrochloride and Bacopa monnieri interaction: a case report

Article

作者: Tandon, Priya ; Macica, Carolyn M ; Acquarulo, Blake

AbstractBackgroundMuscarinic agonists are indicated for the treatment of many conditions including ileus, urinary retention, glaucoma, and Sjögren’s syndrome. Due to their lack of tissue specificity, these drugs can lead to undesirable side effects at off-target sites and may be potentiated by supplements that impact the half-life of these drugs.Case presentationA 58-year-old Caucasian female with history of Sjögren’s syndrome, who was being managed with cevimeline, presented to the primary care office with reported hyperhidrosis, malaise, nausea, and tachycardia. She reported taking an herbal supplement containing B. monnieri and phosphatidylserine the previous night. It has been previously demonstrated that B. monnieri alters cytochrome P450 enzymes. Electrocardiogram showed no acute ST–T changes. Clinical improvement occurred with hydration and discontinuation of the supplement.ConclusionsTo our knowledge, there has only been one other documented cevimeline overdose, and it was not associated with an herbal supplementation interaction. Physicians should actively elicit herbal supplement information from patients to anticipate possible drug–herb interactions. An additional consideration of clinical relevance is the known genetic variability that may affect drug responsiveness due to differences in metabolism and half-life of drugs that arise from common genetic variants of cytochrome P450 genes.

2022-12-01·Systematic Reviews

Safety and efficacy of pilocarpine, cevimeline, and diquafosol compared to artificial tears for the treatment of dry eye: protocol for a systematic review

Article

作者: Graue-Hernandez, Enrique O ; Ramirez-Miranda, Arturo ; Pérez Vázquez, Ana Karen ; Navas, Alejandro ; Serrano-Robles, José Gerardo ; Kahuam-López, Nicolás

AbstractBackgroundDry eye disease (DED) is a condition that compromises the ocular surface and affects millions of people around the world. In recent years, a scheme has been proposed for the treatment of DED, with the use of artificial tear being the mainstay of treatment. In this scheme, the use of secretagogues is suggested as part of the treatment for patients with moderate to severe affectation. With this systematic review, we aim to evaluate the effectiveness and safety of secretagogues for DED.MethodsElectronic databases will be searched; we will include randomized controlled trials that compare secretagogues and artificial tears. Study inclusion will not be restricted on the basis of language or publication status. We will use Google Translate to assess studies written in languages other than English and Spanish. Identification, evaluation, data extraction, and assessment of risk of bias will be conducted by two authors of the review, a third review author will resolve any disagreement. The outcomes will be the ocular surface disease index score, tear film break-up time, Schirmer test score, VRQoL Score, and tear film osmolarity. We will use the Cochrane Collaboration Risk of Bias 2 (RoB 2) tool for assessing the risk of bias of the included studies.Based on the heterogeneity of the included studies, we will combine the findings in a meta-analysis using a fixed effect model if heterogeneity ≤ 50% or a random effect model if heterogeneity > 50%. If we deem meta-analysis as inappropriate, we will document the reasons and report findings from the individual studies narratively.DiscussionBased on the evidence obtained, we will evaluate the effect of pilocarpine, cevimeline, and diquafosol and compare it to artificial tears on multiple outcome measures.This systematic review aims to determine the efficacy and safety of the secretagogues pilocarpine, cevimeline, and diquafosol to help clinicians in the decision-making process.Trial registrationPROSPERO CRD42020218407.

100 项与西维美林相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00661	西维美林	N07AX03	DB00185

研发状态

批准上市

10 条最早获批的记录,

登录

后查看更多信息

适应症	国家/地区	公司	日期
干燥综合征	日本	Nippon Kayaku Co., Ltd.	2001-06-20
干燥综合征	日本	Daiichi Sankyo Co., Ltd.	2001-06-20
干燥综合征	日本	Alfresa Pharma Corp.	2001-06-20
抗合成酶综合征	美国	Cosette Pharmaceuticals, Inc.初创企业	2000-01-11
口干症	美国	Cosette Pharmaceuticals, Inc.初创企业	2000-01-11

未上市

10 条进展最快的记录,

登录

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
头颈部肿瘤	临床1期	美国	Daiichi Sankyo Co., Ltd.	2001-06-01
阿尔茨海默症	临床1期	日本	Nippon Kayaku Co., Ltd.	-
痴呆	临床1期	日本	Snow Brand Milk Products Co., Ltd.	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


Pubmed	N/A	原发性干燥综合征	118	pilocarpine	襯製鹹遞鑰鬱醖衊願膚(積繭願憲鬱獵繭選壓艱) = 鏇觸範廠構襯網蓋憲膚齋積鹹餘餘夢鑰廠製襯 (積願觸憲鑰積網憲網齋 ) 更多	-	2014-07-23
				cevimeline	襯製鹹遞鑰鬱醖衊願膚(積繭願憲鬱獵繭選壓艱) = 選網膚襯齋齋積壓廠襯齋積鹹餘餘夢鑰廠製襯 (積願觸憲鑰積網憲網齋 ) 更多
EULAR2009	N/A	干燥综合征	-	Corticosteroid and Cevimeline	(餘願顧壓獵願鏇選壓願) = 範遞糧襯蓋構積構鑰鹽廠鹽糧壓醖衊願鑰糧糧 (淵鏇壓繭鹽顧繭蓋積製 ) 更多	积极	2009-06-10
				Corticosteroid alone	(餘願顧壓獵願鏇選壓願) = 糧淵窪糧淵夢網鏇壓壓廠鹽糧壓醖衊願鑰糧糧 (淵鏇壓繭鹽顧繭蓋積製 ) 更多
EULAR2011	N/A	原发性干燥综合征	-	Pilocarpine	(夢膚獵窪網餘繭範鹹鏇) = 襯構築廠築膚製窪製襯鹹廠簾觸鏇鹽築範窪簾 (襯淵構積鑰膚糧獵選簾 ) 更多	积极	2011-05-25
				Cevimeline	(夢膚獵窪網餘繭範鹹鏇) = 齋鬱願築觸鏇餘廠糧鏇鹹廠簾觸鏇鹽築範窪簾 (襯淵構積鑰膚糧獵選簾 ) 更多
NCT01690052 (CTgov)	N/A	口干症	15	Cevimeline (Cevimeline)	-	-	2014-08-06
				Pilocarpine (Pilocarpine)